These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 10073046)

  • 1. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
    Fermont I;
    Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
    Lim RR
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Responsibility of the pharmaceutical industry in health safety].
    Santini C
    Ann Pharm Fr; 1999 Jan; 57(1):10-5; discussion 27-8. PubMed ID: 10073046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
    Quartey G; Wang J; Kim J
    Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting.
    Lamarque V; Merle L; Demarez JP;
    Therapie; 2008; 63(4):301-9. PubMed ID: 18937910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sanitary risk: medicinal products and medical devices].
    Marimbert J
    Rev Prat; 2005 Nov; 55(18):2026-32. PubMed ID: 16419907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.
    Leather DA; Davis SC
    Paediatr Respir Rev; 2006 Mar; 7(1):60-6. PubMed ID: 16473819
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.